Bristol-Myers Squibb: Atrial Fibrillation trials

The registry lists 37 Atrial Fibrillation studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 2Phase 3 3Phase 4 3No phase 26(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the HeartCompletedNCT02415400Phase 4Results posted
• A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial FibrillationTerminatedNCT02156076Phase 2Results posted
• Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)CompletedNCT01884350Phase 4Results posted
• A Phase III Study of Apixaban in Patients With Atrial FibrillationCompletedNCT00496769Phase 3Results posted
• Apixaban for the Prevention of Stroke in Subjects With Atrial FibrillationCompletedNCT00412984Phase 3Results posted
• DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial FibrillationCompletedNCT05838781Not applicable
• A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial FibrillationCompletedNCT05232643
• A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)CompletedNCT05044533
• A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in JapanCompletedNCT05027061
• A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of StrokeCompletedNCT04126486Phase 4
• A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.CompletedNCT04045639
• Evaluation of Safety and Effectiveness on Oral AnticoagulantsCompletedNCT03765242
• Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart FailureCompletedNCT03508271
• Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)WithdrawnNCT03508258
• Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection RateCompletedNCT03313167
• A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage CoverageCompletedNCT03189069
• Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial FibrillationWithdrawnNCT03002740
• Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In ItalyCompletedNCT02921126
• Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) PatientsCompletedNCT02792335
• Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.SCompletedNCT02769078
• Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - VenezuelaCompletedNCT02756481
• Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral AnticoagulantsCompletedNCT02754154
• Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in FranceCompletedNCT02714855
• Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the USCompletedNCT02674594
• Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k AntagonistsCompletedNCT02661516
• APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM StudyCompletedNCT02640222
• A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In DenmarkCompletedNCT02591732
• Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2CompletedNCT02488421
• Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)CompletedNCT02447341
• Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using PacemakersTerminatedNCT02153437Phase 1
• Early Post-marketing Study of Eliquis (Apixaban)WithdrawnNCT02153424
• Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial FibrillationCompletedNCT02007655
• Eliquis Regulatory Post Marketing SurveillanceCompletedNCT01885598
• Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation BurdenCompletedNCT01356914Phase 2
• Effect of BMS-914392 on Pharmacokinetics of MetoprololCompletedNCT01211821Phase 1
• Effect of Diltiazem on Pharmacokinetics of BMS-914392CompletedNCT01211808Phase 1
• Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)CompletedNCT00352560Phase 3